Sex Hormones and Thrombosis

Seminars in Hematology

Volumn 44, Issue 2, 2007, Pages 98-105

  Watson, Henry G ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; CYPROTERONE ACETATE; DESOGESTREL; DIANE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; MESTRANOL; NORETHISTERONE; NORETYNODREL; NORGESTIMATE; SEX HORMONE;

ACNE; ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG METABOLISM; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; MONOTHERAPY; PILL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOSIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

AGE FACTORS; BLOOD COAGULATION DISORDERS, INHERITED; CONTRACEPTIVES, ORAL, COMBINED; HORMONE REPLACEMENT THERAPY; HUMANS; META-ANALYSIS; OBESITY; RISK FACTORS; VENOUS THROMBOSIS;

EID: 34047271634     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2007.01.004     Document Type: Article

References (69)

1. Wu O., Robertson L., Twaddle S., Lowe G., Clark P., Walker I., et al. Screening for thrombophilia in high-risk situations: A meta-analysis and cost-effectiveness analysis. Br J Haematol 131 (2005) 80-90
2. United Nations Population Division. World Contraceptive Use 2001 (2002), United Nations, New York, NY
3. Beral V., Banks E., Reeves G., and Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4 (1999) 191-210
4. Jordan W.M. Pulmonary embolism. Br Med J 2 (1961) 1146-1147
5. Boyce J., Fawcett J.W., and Noall E.W. Coronary thrombosis and Conovide. Lancet 1 (1963) 111
6. Lorentz I. Parietal lesions and Enavid. Br Med J 2 (1962) 1191-1191
7. Daly E., Vessey M.P., Hawkins M.M., Carson J.L., Gough P., and Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 348 (1996) 977-980
8. Grodstein F., Stampfer M.J., Goldhaber S.Z., Manson J.E., Colditz G.A., Speizer F.E., et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 348 (1996) 983-987
9. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
10. Meade T.W., Haines A.P., North W.R., Chakrabarti R., Howarth D.J., and Stirling Y. Haemostatic, lipid, and blood-pressure profiles of women on oral contraceptives containing 50 microgram or 30 microgram oestrogen. Lancet 2 (1977) 948-951
11. Quehenberger P., Loner U., Kapiotis S., Handler S., Schneider B., Huber J., et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 76 (1996) 729-734
12. Scarabin P.Y., Plu-Bureau, Zitoun D., Bara L., Guize L., and Samama M.M. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: Absence of dose-dependent effect on PAI-1 activity. Thromb Haemost 74 (1995) 928-932
13. World Health Organization. A multicentre study of coagulation and haemostatic variables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 98 (1991) 1117-1128
14. Rosing J., Tans G., Nicolaes G.A., Thomassen M.C., van O.R., van der Ploeg P.M., et al. Oral contraceptives and venous thrombosis: Different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 97 (1997) 233-238
15. Rosing J., Middeldorp S., Curvers J., Christella M., Thomassen L.G., Nicolaes G.A., et al. Low-dose oral contraceptives and acquired resistance to activated protein C: A randomised cross-over study. Lancet 354 (1999) 2036-2040
16. Tans G., Curvers J., Middeldorp S., Thomassen M.C., Meijers J.C., Prins M.H., et al. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 84 (2000) 15-21
17. Acs N., Vajo Z., Miklos Z., Siklosi G., Paulin F., Felicetta J.V., et al. The effects of postmenopausal hormone replacement therapy on hemostatic variables: A meta-analysis of 46 studies. Gynecol Endocrinol 16 (2002) 335-346
18. Middeldorp S., Meijers J.C., van den Ende A.E., van E.A., Bouma B.N., Tans G., et al. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: A cross-over study. Thromb Haemost 84 (2000) 4-8
19. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., and Vandenbroucke J.P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 160 (2000) 49-52
20. Herings R.M., Urquhart J., and Leufkens H.G. Venous thromboembolism among new users of different oral contraceptives. Lancet 354 (1999) 127-128
21. Bloemenkamp K.W., Rosendaal F.R., Helmerhorst F.M., Buller H.R., and Vandenbroucke J.P. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 346 (1995) 1593-1596
22. Gerstman B.B., Piper J.M., Tomita D.K., Ferguson W.J., Stadel B.V., and Lundin F.E. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 133 (1991) 32-37
23. Oral contraception and thrombo-embolic disease. J R Coll Gen Pract 13 (1967) 267-279
24. Gomes M.P., and Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: A clinical review. Arch Intern Med 164 (2004) 1965-1976
25. Koster T., Small R.A., Rosendaal F.R., and Helmerhorst F.M. Oral contraceptives and venous thromboembolism: A quantitative discussion of the uncertainties. J Intern Med 238 (1995) 31-37
26. Gerstman B.B., Piper J.M., Freiman J.P., Tomita D.K., Kennedy D.L., Ferguson W.J., et al. Oral contraceptive oestrogen and progestin potencies and the incidence of deep venous thromboembolism. Int J Epidemiol 19 (1990) 931-936
27. Bloemenkamp K.W., Rosendaal F.R., Buller H.R., Helmerhorst F.M., Colly L.P., and Vandenbroucke J.P. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 159 (1999) 65-70
28. Lidegaard O., Edstrom B., and Kreiner S. Oral contraceptives and venous thromboembolism: A five-year national case-control study. Contraception 65 (2002) 187-196
29. Jick H., Jick S.S., Gurewich V., Myers M.W., and Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 346 (1995) 1589-1593
30. World Health Organization. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 346 (1995) 1582-1588
31. Hennessy S., Berlin J.A., Kinman J.L., Margolis D.J., Marcus S.M., and Strom B.L. Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: A meta-analysis and formal sensitivity analysis. Contraception 64 (2001) 125-133
32. Kemmeren J.M., Algra A., and Grobbee D.E. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. BMJ 323 (2001) 131-134
33. Royal College of Obstetricians and Gynaecologists. Venous thromboembolism and hormonal contraception. Guideline 40 (2004) 1-13
34. Jick S.S., and Jick H. Cerebral venous sinus thrombosis in users of four hormonal contraceptives: Levonorgestrel-containing oral contraceptives, norgestimate-containing oral contraceptives, desogestrel-containing oral contraceptives and the contraceptive patch. Contraception 74 (2006) 290-292
35. Vasilakis-Scaramozza C., and Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 358 (2001) 1427-1429
36. Seaman H.E., de Vries C.S., and Farmer R.D. Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette): Observational studies using the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 13 (2004) 427-436
37. Spitzer W.O. Cyproterone acetate with ethinylestradiol as a risk factor for venous thromboembolism: An epidemiological evaluation. J Obstet Gynaecol Can 25 (2003) 1011-1018
38. Pearce H.M., Layton D., Wilton L.V., and Shakir S.A. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol 60 (2005) 98-102
39. Heinemann L.A., and Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 27 (2004) 1001-1018
40. Jick S.S., Kaye J.A., Russmann S., and Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception 73 (2006) 223-228
41. Vasilakis C., Jick H., and del M.M.-M. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 354 (1999) 1610-1611
42. Poulter N.R., Chang C.L., Farley T.M., and Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet 354 (1999) 1610
43. World Health Organization. A multinational case-control study of cardiovascular disease and steroid hormone contraceptives. J Clin Endocrinol Metab 48 (1995) 1513-1547
44. Grady D., Wenger N.K., Herrington D., Khan S., Furberg C., Hunninghake D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132 (2000) 689-696
45. Beral V., Banks E., and Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 360 (2002) 942-944
46. Jick H., Derby L.E., Myers M.W., Vasilakis C., and Newton K.M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 348 (1996) 981-983
47. Perez G.S., Garcia Rodriguez L.A., Castellsague J., and Duque O.A. Hormone replacement therapy and risk of venous thromboembolism: Population based case-control study. BMJ 314 (1997) 796-800
48. Varas-Lorenzo C., Garcia-Rodriguez L.A., Cattaruzzi C., Troncon M.G., Agostinis L., and Perez-Gutthann S. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: A population-based study in southern Europe. Am J Epidemiol 147 (1998) 387-390
49. Douketis J.D., Julian J.A., Kearon C., Anderson D.R., Crowther M.A., Bates S.M., et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis?. A prospective case-control study. J Thromb Haemost 3 (2005) 943-948
50. Smith N.L., Heckbert S.R., Lemaitre R.N., Reiner A.P., Lumley T., Weiss N.S., et al. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 292 (2004) 1581-1587
51. Scarabin P.Y., Oger E., and Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 362 (2003) 428-432
52. Straczek C., Oger E., Yon de Jonage-Canonico M.B., Plu-Bureau G., Conard J., Meyer G., et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration. Circulation 112 (2005) 3495-3500
53. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: Results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 346 (1995) 1575-1582
54. Suissa S., Spitzer W.O., Rainville B., Cusson J., Lewis M., and Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 15 (2000) 817-821
55. Abdollahi M., Cushman M., and Rosendaal F.R. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 89 (2003) 493-498
56. Cushman M., Kuller L.H., Prentice R., Rodabough R.J., Psaty B.M., Stafford R.S., et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 292 (2004) 1573-1580
57. Farmer R.D., Lawrenson R.A., Thompson C.R., Kennedy J.G., and Hambleton I.R. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 349 (1997) 83-88
58. Farmer R.D., Lawrenson R.A., Todd J.C., Williams T.J., MacRae K.D., Tyrer F., et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 49 (2000) 580-590
59. Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., and Sandset P.M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-Results of the randomized, double-blind, placebo-controlled Estrogen in Venous Thromboembolism Trial (EVTET). Thromb Haemost 84 (2000) 961-967
60. Vessey M.P., Doll R., Fairbairn A.S., and Glober G. Postoperative thromboembolism and the use of oral contraceptives. Br Med J 3 (1970) 123-126
61. Royal College of Obstetricians and Gynaecologists. Hormone Replacement Therapy and Venous Thromboembolism (2004), Royal College of Obstetricians and Gynaecologists, London, UK 1-9 Guideline No 19
62. Baglin T., Luddington R., Brown K., and Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: Prospective cohort study. Lancet 362 (2003) 523-526
63. Martinelli I., Mannucci P.M., Taioli E., Rossi V., Crosti F., et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. De S, V. Blood 92 (1998) 2353-2358
64. Simioni P., Sanson B.J., Prandoni P., Tormene D., Friederich P.W., Girolami B., et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 81 (1999) 198-202
65. Vandenbroucke J.P., Koster T., Briet E., Reitsma P.H., Bertina R.M., and Rosendaal F.R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 344 (1994) 1453-1457
66. Rosendaal F.R., Koster T., Vandenbroucke J.P., and Reitsma P.H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85 (1995) 1504-1508
67. Martinelli I., Taioli E., Bucciarelli P., Akhavan S., and Mannucci P.M. Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 19 (1999) 700-703
68. Wu O., Robertson L., Langhorne P., Twaddle S., Lowe G.D., Clark P., et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: A systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Thromb Haemost 94 (2005) 17-25
69. Lowe G., Woodward M., Vessey M., Rumley A., Gough P., and Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy. Thromb Haemost 83 (2000) 530-535